Bio-Techne price target raised to $73 from $68 at Baird

Baird raised the firm’s price target on Bio-Techne to $73 from $68 and keeps an Outperform rating on the shares. The firm said though management noted signs of market stabilization in December/January, the company expects 3Q organic revenue to be similar toQ2. Baird thinks shares could remain pressured until there’s improved visibility around a return to growth, let alone double-digit growth.